AstraZeneca Brazil

07.08.2025 - 18:02:39

Anvisa aprova primeira imunoterapia para tratamento de câncer de pulmão estágio limitado que pode reduzir em até 27% o risco de morte de pacientes

e siga a empresa no Instagram @astrazenecabr.??

Material destinado a veículos de imprensa. BR-36935. Aprovado dez/24.

1 DOU. RESOLUÇÃO-RE nº 4.411, DE 28 DE NOVEMBRO DE 2024. Disponível: https://www.in.gov.br/en/web/dou/-/resolucao-re-n-4.411-de-28-de-novembro-de-2024-598832735. Acesso em 02/12/24.
2 The New England Journal of Medicine. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. Disponível: https://www.nejm.org/doi/full/10.1056/NEJMoa2404873. Acesso em 27/11/24.
3 Faivre-Finn C; et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017;18:1116–1125;
4 Grønberg BH; et al. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncol 2016;55:591–597;
5 Peters S, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol 2022;33:67–79;
6 Simon GR, et al. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:324S-339S; 5. Pietanza MC, et al. Small cell lung cancer: will recent progress lead to improved outcomes?. Clin Cancer Res 2015;21:2244–2255;
7 NCCN. Clinical Practice Guidelines in Oncology. Small cell lung cancer. Version 3.2025. Disponível: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Acesso em 04/11/24;
8 Turrisi AT 3rd; et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 1999 Jan 28;340(4):265-71;
9 ACS. Lung Cancer Survival Rates. Disponível: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html. Acesso em 04/11/24.
10 Blackhall F, Girard N, Livartowski A, et al. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study. BMJ Open. Published online February 6, 2023;
11 National Cancer Institute. NCI Dictionary - Small Cell Lung Cancer. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-cell-lung-cancer.
12 Qin A and Kalemkerian GP. Treatment Options for Relapsed Small-Cell Lung Cancer: What Progress Have We Made? J Oncol Pract. 2018;14(6):369-370.
13 Bebb DG, et al. Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers. Pulm Ther. 2023:9;435-450.
14 NCCN. Clinical Practice Guidelines in Oncology. Small cell lung cancer. Version 3.2025. Disponível: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Acesso em 28/11/24.
15 MOC. Tumores sólidos-Pulmão.Células Pequenas (2025). Disponível: https://mocbrasil.com/moc-tumores-solidos/cancer-de-pulmao/5-pulmao-celulas-pequenas/. Acesso em 28/11/24.